`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`APOTEX CORP.
`Petitioner
`v.
`ALCON RESEARCH, LTD.
`Patent Owner
`
`U.S. Patent No. 8,268,299 to Kabra et al.
`Issue Date: September 18, 2012
`Title: Self Preserved Aqueous Pharmaceutical Compositions
`
`_____________________
`
`Inter Partes Review No. Unassigned
`_____________________
`
`APOTEX CORP.'S EXHIBIT LIST
` (INTER PARTES REVIEW OF U.S. PATENT NO. 8,268,299)
`
`
`
`
`
`
`Mail Stop "PATENT BOARD"
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`
`APOTEX CORP. EXHIBIT LIST
`Inter Partes Review of U.S. Patent No. 8,268,299
`
`
`Description
`
`Apotex
`Exhibit #
`1001 Kabra et al., U.S. Patent No. 8,268,299, "Self Preserved Aqueous
`Pharmaceutical Compositions" (filed September 20, 2007; issued
`September 18, 2012)
`1002 Declaration of Michael J. Miller, Ph.D.
`1003 Xia et al., WO 2005/097067, "Zinc Preservative Composition and
`Method of Use" (filed March 24, 2005; published October 20, 2005)
`Chowhan et al., U.S. Patent No. 6,143,799, "Use of Borate-Polyol
`Complexes in Ophthalmic Compositions" (filed July 2, 1998; issued
`November 7, 2000)
`1005 Gadd et al., "Microorganisms and Heavy Metal Toxicity," Microbial
`Ecology, 4:303-317 (1978)
`FDA Approved Drug Label "TRAVATAN® (travoprost ophthalmic
`solution) 0.004% Sterile" (2001)
`Certified English translation of Kiyobayashi, JP 2003-104870,
`"Aqueous Composition" (filed September 28, 2001; issued April 9,
`2003)
`1008
`File history of U.S. Patent No. 8,268,299
`1009 Kiyobayashi, JP 2003-104870, "Aqueous Composition" (filed
`September 28, 2001; published April 9, 2003)
`File history of U.S. Patent No. 8,323,630
`File history of U.S. Patent No. 8,388,941
`Sheftel, "Indirect Food Additives and Polymers: Migration and
`Toxicology," p. 422 (2000)
`The European Agency for the Evaluation of Medicinal Products,
`Veterinary Medicines Evaluation Unit, "Polyoxyl Castor Oil, Polyoxyl
`Hydrogenated Castor Oil Summary Report" (1999)
`"Antimicrobial Effectiveness Testing," in The United States
`Pharmacopeia 26: The National Formulary 22, pp. 2002-2004 (2003)
`Curriculum Vitae of Michael J. Miller, Ph.D.
`
`1004
`
`1006
`
`1007
`
`1010
`1011
`1012
`
`1013
`
`1014
`
`1015
`
`
`
`
`- 2 -
`
`
`
`Apotex
`Exhibit #
`1016
`
`APOTEX CORP. EXHIBIT LIST
`Inter Partes Review of U.S. Patent No. 8,268,299
`
`
`Description
`
`FORM 6-K, SECURITIES AND EXCHANGE COMMISSION, For
`the month of May 2002, ALCON, INC.
`
`
`
`Respectfully submitted,
`
`
`
` /Eldora L. Ellison/
`Eldora L. Ellison (Reg. No. 39,967)
`Lead Attorney for Petitioner Apotex Corp.
`
`
`
`
`Date: July 5, 2013
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`1100 New York Avenue, N.W.
`Washington, D.C. 20005-3934
`(202) 371-2600
`
`
`
`- 3 -
`
`
`
`APOTEX CORP. EXHIBIT LIST
`Inter Partes Review of U.S. Patent No. 8,268,299
`
`
`CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e), 42.105(a))
`
`The undersigned hereby certifies that the above-captioned "Apotex Corp.'s Exhibit
`
`List" and Exhibits 1001 - 1016 were served in their entirety on July 5, 2013, upon the
`
`following party via FEDEX®:
`
`Alcon
`IP Legal, TB4-8
`6201 South Freeway
`
`Fort Worth, TX 76134-2099
`Patent owner's correspondence address
`of record for U.S. Patent No. 8,268,299
`
`
`
`
`
` STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`
`
`
`
`
` /Eldora L. Ellison/
`
` Eldora L. Ellison
`Date: July 5, 2013
` Lead Attorney for Petitioner Apotex
`
`
`
`
`
`1100 New York Avenue, N.W. Registration No. 39,967
`Washington, D.C. 20005 - 3934
`(202) 371-2600
`
`1710012_1
`
`
`
`- 4 -
`
`